These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 19052483

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.
    Konopnicki D, De Wit S, Poll B, Crommentuyn K, Huitema A, Clumeck N.
    HIV Med; 2005 Jan; 6(1):1-6. PubMed ID: 15670245
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR).
    Wasmuth JC, la Porte CJ, Schneider K, Burger DM, Rockstroh JK.
    Antivir Ther; 2004 Apr; 9(2):213-20. PubMed ID: 15134183
    [Abstract] [Full Text] [Related]

  • 6. Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.
    Duval X, Peytavin G, Albert I, Bénoliel S, Ecobichon JL, Brun-Vézinet F, Mentré F, Leport C, Vildé JL.
    HIV Med; 2004 Jul; 5(4):307-13. PubMed ID: 15236622
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients.
    Rhame FS, Rawlins SL, Petruschke RA, Erb TA, Winchell GA, Wilson HM, Edelman JM, Abramson MA.
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4200-8. PubMed ID: 15504842
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and plasma concentrations of indinavir when boosted with ritonavir in human immunodeficiency virus-infected Thai children.
    Plipat N, Cressey TR, Vanprapar N, Chokephaibulkit K.
    Pediatr Infect Dis J; 2007 Jan; 26(1):86-8. PubMed ID: 17195716
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.
    Boyd M, Mootsikapun P, Burger D, Chuenyam T, Ubolyam S, Mahanontharit A, Sangkote J, Bunyaprawit P, Horsakulchai M, Lange J, Cooper D, Phanuphak P, Ruxrungtham K.
    Antivir Ther; 2005 Jan; 10(2):301-7. PubMed ID: 15865224
    [Abstract] [Full Text] [Related]

  • 11. Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children.
    Pelton SI, Stanley K, Yogev R, Fletcher CV, McIntosh K, Wiznia A, Nachman S, Pediatric AIDS Clinical Trials Group 338 Study Team.
    Clin Infect Dis; 2005 Apr 15; 40(8):1181-7. PubMed ID: 15791520
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir.
    Cressey TR, Urien S, Hirt D, Halue G, Techapornroong M, Bowonwatanuwong C, Leenasirimakul P, Treluyer JM, Jourdain G, Lallemant M, PHPT-3 Team.
    Ther Drug Monit; 2011 Feb 15; 33(1):25-31. PubMed ID: 21233689
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability.
    Cressey TR, Leenasirimakul P, Jourdain G, Tod M, Sukrakanchana PO, Kunkeaw S, Puttimit C, Lallemant M.
    J Antimicrob Chemother; 2005 Jun 15; 55(6):1041-4. PubMed ID: 15883177
    [Abstract] [Full Text] [Related]

  • 17. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.
    Dragsted UB, Gerstoft J, Pedersen C, Peters B, Duran A, Obel N, Castagna A, Cahn P, Clumeck N, Bruun JN, Benetucci J, Hill A, Cassetti I, Vernazza P, Youle M, Fox Z, Lundgren JD, MaxCmin1 Trial Group.
    J Infect Dis; 2003 Sep 01; 188(5):635-42. PubMed ID: 12934178
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Indinavir-ritonavir combination: pharmacologic results and tolerance in patients infected by HIV].
    Bani-Sadr F, Perré P, Peytavin G, Bernard L, Melchior JC, Perronne C, de Truchis P.
    Presse Med; 2001 Apr 21; 30(15):731-5. PubMed ID: 11360738
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.